Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality.
about
Update on pre-diabetes: Focus on diagnostic criteria and cardiovascular riskMetrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters.Genome-wide association study of 1,5-anhydroglucitol identifies novel genetic loci linked to glucose metabolism.Racial Differences in and Prognostic Value of Biomarkers of Hyperglycemia.Do glycemic marker levels vary by race? Differing results from a cross-sectional analysis of individuals with and without diagnosed diabetes.Relationship of glycemic control markers - 1,5 anhydroglucitol, fructosamine, and glycated hemoglobin among Asian Indians with different degrees of glucose intolerance.Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention.Effects of dietary carbohydrate on 1,5-anhydroglucitol in a population without diabetes: results from the OmniCarb trial.Serum Levels of 1,5-Anhydroglucitol and Risk of Incident End-Stage Renal Disease.Glucose Peaks and the Risk of Dementia and 20-Year Cognitive Decline.Risk prediction of major complications in individuals with diabetes: the Atherosclerosis Risk in Communities Study.Association of a Biomarker of Glucose Peaks, 1,5-Anhydroglucitol, With Subclinical Cardiovascular DiseaseLow 1,5-anhydroglucitol levels are associated with long-term cardiac mortality in acute coronary syndrome patients with hemoglobin A1c levels less than 7.0.Comparative Agreement Analysis of Differences in 1,5-Anhydroglucitol, Glycated Albumin, and Glycated Hemoglobin A1c Levels between Fasting and Postprandial States in Steamed Bread Meal Test.Serum 1,5-Anhydroglucitol: Risk Factor of Acute Ischemic Stroke and Transient Ischemic Attack in Well-Controlled Diabetes.The metabolism and transport of 1,5-anhydroglucitol in cells.Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes.The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis
P2860
Q28073749-736EAAA8-59B3-4B3C-9753-B7976C6DAE1BQ33727475-13D4FCA6-B43F-4869-93F2-E5F7D2BA3FD5Q33767379-D079B505-EE1C-4CF0-A466-32CE2BD650B5Q36726169-7D364BE3-A05F-4983-BC0D-9F67C5E48E83Q37007055-3ACC3A81-E5C0-4D5F-90D7-CD6F81CF7D77Q37292095-C9DD6553-350E-46D9-A1CC-A5988B34388BQ37326200-5AF28651-C907-42E4-9B27-6697BF2B217EQ40176072-C883E086-4090-4F0F-B57A-016B871262BBQ40189389-310470A4-EFA3-4BAF-BCC1-AC91D880A295Q40203146-1E907AFF-7F1B-46DA-ACFB-ED26C0F641BDQ40762736-937D4256-61A9-4417-8BDE-C316F9A9B1D4Q41640157-9CFBC38A-411E-4441-A7B9-068E418476A9Q46960793-90A43E28-CD5E-473F-980D-6E742E2FFC0BQ47115413-F69B2C37-CE3F-4C65-A481-90C31C917B7FQ47999757-B023654A-0D60-409B-BCC5-AF6D29D47CE3Q48274733-53E3C83E-284A-4F32-825A-862D55950F52Q51052616-95BDF53E-BA63-4F9D-A916-3852D29B882FQ57412755-4726E393-2E1E-4580-9F93-9C65E6C536C5
P2860
Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality.
@ast
Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality.
@en
type
label
Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality.
@ast
Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality.
@en
prefLabel
Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality.
@ast
Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality.
@en
P2093
P2860
P50
P356
P1433
P1476
Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality.
@en
P2093
Michael Steffes
Nisa Maruthur
Pamela Lutsey
P2860
P304
P356
10.2337/DB15-0607
P407
P577
2015-09-22T00:00:00Z